Browse by category

The long-term use of proton pump inhibitors (PPIs), a class of drugs widely used to treat acid reflux and ulcers, may not be linked to any increased risk of developing gastric adenocarcinoma, according to a study of Nordic health data. "The results of this study do not support the hypothesis that long-term proton pump inhibitor use is associated with an increased risk of gastric adenocarcinoma,” the researchers noted. “This finding should offer relief for patients needing lon

Metabolic bariatric surgery (MBS) may improve psoriasis severity, quality of life and treatment requirements - weight loss magnitude, type of MBS and patient characteristics might affect clinical response of psoriasis, however, the current evidence is uncertain, according to researchers from Hull University Teaching Hospitals NHS Trust, in the UK. (Credit: Bobjgalindo) The researchers noted that although MBS has been associated with improved clinical outcomes of psoriasis, ye

The postoperative complications of medical tourism may be costing the NHS up to £20,000 per patient, suggest the findings of a rapid review of the available data performed by UK researchers. However, data on the use, frequency and consequences for the NHS are incomplete and haphazard, making it currently impossible to fully understand the risks of opting for surgery overseas, the researchers warned. "There are areas of the UK, such as Wales and the South West of England, whic

Kailera Therapeutics has announced the randomisation of the first participants in the KaiNETIC global Phase 3 clinical program of ribupatide (also known as KAI-9531), an investigational once-weekly injectable dual GLP-1/GIP receptor agonist peptide, for the treatment of people living with obesity or overweight. The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3

Outcomes from Viking Therapeutics’ Phase 2 VENTURE clinical trial of VK2735 - a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors – reveal that after 13 weekly subcutaneous doses, participants receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7% with no signs of plateau. The outcomes highlights the previously reported positive results from th

Both the new weight loss drugs and bariatric surgery improve body composition in patients with obesity by inducing a moderate loss of fat-free mass (including lean muscle) along with a substantial reduction in fat, researchers at Vanderbilt Health have found. Weight loss study team: From left, Danxia Yu, PhD, Zicheng Wang, MS, Lei Wang, PhD, and Jason Samuels, MD, are co-authors of a paper evaluating body composition changes after bariatric surgery or treatment with the new w